In brief: Living Cell Technologies, Phosphagenics, Rockeby, Antisense, Prima, Proteome Systems
Friday, 14 October, 2005
Living Cell Technologies (ASX:LCT) has appointed US based neuroscientist Dr Dwaine F Emerich as chief scientific officer of LCT BioPharma. He has been LCT's US vice-president of research since 2003, joining the company from Sertoli Technologies.
Phosphagenics' (ASX:POH) has appointed Dr Esra Ogru, vice-president of research & development, to the board of directors.
Rockeby biomed (ASX:RBY) has signed a five-year exclusive agreement with Pharmaplan South Africa for the marketing and distribution of CanDia5, its point-of-care test kit to detect Vulvo-Vaginal Candidiasis, in South Africa. The sales of CanDia5 through Pharmaplan are expected to generate revenue for Rockeby in the current financial year.
Antisense Therapeutics' (ASX:ANP) development director Dr Jega Iswaran has resigned. The company's clinical development program will now be overseen by development manager, Nuket Desem.
Prima Biomed (ASX:PRR) has completed inital recruitment of its phase IIa clinical trial in ovarian cancer at the Austin Hospital in Melbourne.
Proteome Systems (ASX:PXL) has signed a heads of agreement with Prince Henry's Institute Medical Research (PHIMR) to combine their IP to develop an ovarian cancer diagnostic test.
Oxytocin analogue treats chronic abdominal pain
Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
